Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.
作者信息
Khaddour Karam, Dowling Joshua, Huang Jiayi, Council Martha, Chen David, Cornelius Lynn, Johanns Tanner, Dahiya Sonika, Ansstas George
机构信息
Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
出版信息
Oncotarget. 2023 Feb 11;14:126. doi: 10.18632/oncotarget.28365.
Abstract
摘要
相似文献
1
Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.附录：序贯使用瘤内注射溶瘤性单纯疱疹病毒（TVEC）和帕博利珠单抗，随后使用替莫唑胺成功治疗获得性B2M突变的免疫治疗难治性颅内转移性黑色素瘤。
Oncotarget. 2023 Feb 11;14:126. doi: 10.18632/oncotarget.28365.
2
Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.对于伴有获得性B2M突变的免疫治疗难治性颅内转移性黑色素瘤，序贯使用瘤内注射重组溶瘤性单纯疱疹病毒（TVEC）和帕博利珠单抗，随后使用替莫唑胺，治疗成功。
Oncotarget. 2020 Dec 29;11(52):4836-4844. doi: 10.18632/oncotarget.27848.
3
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.在接受派姆单抗治疗失败的转移性黑色素瘤患者中，序贯替莫唑胺节拍化疗可产生显著缓解。
Melanoma Res. 2019 Dec;29(6):643-647. doi: 10.1097/CMR.0000000000000592.
4
Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma.立体定向体部放射治疗（SBRT）与talimogene laherparepvec（TVEC）联合使用，随后使用伊匹单抗治疗难治性转移性黑色素瘤实现持久完全缓解。
Cureus. 2022 Sep 25;14(9):e29573. doi: 10.7759/cureus.29573. eCollection 2022 Sep.
5
Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.黑色素瘤中 MAP2K2 和 B2M 突变介导的 BRAF/MEK 和免疫检查点抑制剂序贯治疗失败。
Exp Mol Pathol. 2019 Oct;110:104260. doi: 10.1016/j.yexmp.2019.104260. Epub 2019 May 11.
6
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.与黑色素瘤中PD-1阻断获得性耐药相关的突变
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
7
Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China.帕博利珠单抗联合替莫唑胺治疗不可切除的晚期黑色素瘤：一项中国多中心回顾性分析
Ann Transl Med. 2021 Nov;9(21):1625. doi: 10.21037/atm-21-5738.
8
Intralesional and systemic immunotherapy for metastatic melanoma.转移性黑色素瘤的瘤内和全身免疫治疗。
Expert Opin Biol Ther. 2016 Dec;16(12):1491-1499. doi: 10.1080/14712598.2016.1233961. Epub 2016 Sep 20.
9
Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.黑色素瘤转移灶经talimogene laherparepvec治疗引起的慢性肉芽肿性皮炎。
J Cutan Pathol. 2018 Jan;45(1):48-53. doi: 10.1111/cup.13048. Epub 2017 Oct 26.
10
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.自身免疫性溶血性贫血和全血细胞减少作为帕博利珠单抗治疗转移性黑色素瘤的并发症：一例报告
Case Rep Oncol. 2019 Jun 19;12(2):456-465. doi: 10.1159/000500856. eCollection 2019 May-Aug.
Zotero 插件